<DOC>
	<DOC>NCT02600351</DOC>
	<brief_summary>This study will evaluate the efficacy, safety and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) for 12 weeks with or without ribavirin (RBV) in participants without cirrhosis, and LDV/SOF FDC for 12 weeks with RBV or LDV/SOF FDC for 24 weeks without RBV in participants with cirrhosis.</brief_summary>
	<brief_title>Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
	<criteria>HCV RNA &gt; 15 IU/mL at screening HCV genotype 1 or 4 Chronic HCV infection (≥ 6 months) Prior virologic failure after treatment with SOF in combination with simeprevir (SMV) ± RBV or with RBV ± PEG Cirrhotic and noncirrhotic as determined by standard methods Male and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception Prior exposure to approved or experimental nonstructural protein (NS5A) inhibitors Prior exposure to nucleos(t)ide polymerase inhibitors, other than SOF Pregnant or nursing female or male with pregnant female partner Coinfection with HIV or hepatitis B virus Current or prior history of clinical hepatic decompensation Hepatocellular carcinoma or other malignancy (with exception of certain resolved skin cancers) Chronic use of systemic immunosuppressive agents History of clinically significant illness or any other medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Hepatitis C Virus (HCV)</keyword>
	<keyword>Ledipasvir/Sofosbuvir</keyword>
	<keyword>Ribavirin</keyword>
</DOC>